Genitourinary Cancers | Topics

 
Advice for Community Oncologists Treating Renal Cell Carcinoma
May 09, 2022

Dr Scott Tykodi provides advice for community oncologists managing patients with renal cell carcinoma.

Common Adverse Events with Single-Agent or Combination Therapy
May 05, 2022

Mehmet Asim Bilen, MD, provides an overview of commonly observed adverse events in patients with metastatic RCC receiving single-agent or combination therapy.

Safety and Efficacy Data: The CLEAR Trial
May 05, 2022

David Aggen, MD, PhD, reviews data from the CLEAR trial, which assessed the safety and efficacy of lenvatinib/pembrolizumab versus sunitinib.

Strategies and Barriers in mUC Maintenance Therapy
May 02, 2022

Panel members share insights into strategies and barriers to maintenance therapy for patients with bladder cancer.

Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy
May 02, 2022

Thomas Powles, MBBS, MRCP, MD, comments on patient-reported outcome data and quality of life data in patients receiving maintenance therapy for metastatic urothelial cancer.

Conclusions: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
May 02, 2022

Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.

The Exciting Future of Advanced Renal Cell Carcinoma Management
May 02, 2022

A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.

Unmet Needs in Advanced Renal Cell Carcinoma Management
May 02, 2022

Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.

Safety and Efficacy Data: The CheckMate 9ER Trial
May 02, 2022

Robert Alter, MD, reviews the CheckMate 9ER trial of cabozantinib/nivolumab versus sunitinib in advanced renal cell cancer.

Safety and Efficacy Data: The KEYNOTE-426 Trial
May 02, 2022

Arnab Basu, MD, MPH, FACP discusses data from the KEYNOTE-426 trial of axitinib/pembrolizumab versus sunitinib in metastatic RCC.